# Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Source: https://onco.cc/trials/nct06419634/  
OnCo record `nct06419634` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of ORM-6151 (BMS-986497) run by Bristol-Myers Squibb, terminated.

## Summary

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome is a phase 1 interventional study registered as NCT06419634 by Bristol-Myers Squibb, with 34 participants enrolled, started 2024-05-29. Conditions recorded: Acute Myeloid Leukemia and Myelodysplastic Syndrome. Interventions recorded: BMS-986497, Azacitidine and Venetoclax.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06419634
- Phase: 1
- Setting: Phase I Multicenter, Open-Label, First-in-Human Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double Combination With Azacitidine and in Triple Combination With Azacitidine and Venetoclax in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Sponsor: Bristol-Myers Squibb
- Enrolled: 34

## Sources

- ClinicalTrials.gov NCT06419634: https://clinicaltrials.gov/study/NCT06419634

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- drugs: [ORM-6151 (BMS-986497)](https://onco.cc/drugs/orm-6151/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/), [Orum Therapeutics](https://onco.cc/companies/orum-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06419634.json